journal article·2022-09Open access

A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy

Taokun Luo, Geoffrey T. Nash, Xiaomin Jiang, Xuanyu Feng, Jianming Mao, Jianqiao Liu, Aditya Juloori, Alexander T. Pearson, Wenbin Lin

Advanced Materials· Volume 34· Issue 39

Abstract

Abstract Despite potent preclinical antitumor activity, activation of stimulator of interferon genes (STING) has shown modest therapeutic effects in clinical studies. Many STING agonists, including 2′,3′‐cyclic guanosine monophosphate–adenosine monophosphate (cGAMP), show poor pharmacokinetic properties for sustaining STING activation in tumors and achieving optimal antitumor efficacy. Improved delivery of STING agonists and their effective combination with other treatments are needed to enhance their therapeutic effects. Herein, a 2D nanoplatform, cGAMP/MOL, is reported via conjugating cGAMP to a nanoscale metal–organic layer (MOL) for simultaneous STING activation and radiosensitization. The MOL not only exhibits strong radiosensitization effects for enhanced cancer killing and induction of immunogenic cell death, but also retains cGAMP in tumors for sustained STING activation. Compared to free cGAMP, cGAMP/MOL elicits stronger STING activation and regresses local tumors upon X‐ray irradiation. Further combination with an immune checkpoint inhibitor bridges innate and adaptive immune systems by activating the tumor microenvironment to elicit systemic antitumor responses.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: interferon and immune responses · Nanoplatforms for cancer theranostics · Peptidase Inhibition and Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry The University of Chicago Chicago IL 60637 USA

Department of Radiation and Cellular Oncology and the Ludwig Center for Metastasis Research The University of Chicago Chicago IL 60637 USA

Department of Pathology & University of Chicago Comprehensive Cancer Center The University of Chicago Chicago IL 60637 USA

Funding

National Cancer Institute

References (57)

Show source-provided references
1. 10.1038/nrendo.2016.20510.1038/nrendo.2016.205 ↗
2. 10.1038/s41591-019-0564-610.1038/s41591-019-0564-6 ↗
3. 10.1038/cr.2016.14910.1038/cr.2016.149 ↗
4. 10.1038/s41586-019-1593-510.1038/s41586-019-1593-5 ↗
5. 10.1186/s12943-019-1087-y10.1186/s12943-019-1087-y ↗
6. 10.1126/science.123245810.1126/science.1232458 ↗
7. 10.1126/science.122996310.1126/science.1229963 ↗
8. 10.3390/jcm910332310.3390/jcm9103323 ↗
9. 10.1038/s41467-017-01566-510.1038/s41467-017-01566-5 ↗
10. 10.1093/annonc/mdy424.01510.1093/annonc/mdy424.015 ↗
11. 10.1200/JCO.2019.37.15_suppl.250710.1200/JCO.2019.37.15_suppl.2507 ↗
12. 10.1038/s41578-019-0108-110.1038/s41578-019-0108-1 ↗
13. 10.1038/s41551-020-00675-910.1038/s41551-020-00675-9 ↗
14. 10.1038/nrc300710.1038/nrc3007 ↗
15. 10.1038/nrclinonc.2016.21110.1038/nrclinonc.2016.211 ↗
16. 10.1186/s40425-016-0156-710.1186/s40425-016-0156-7 ↗
17. 10.1001/jamaoncol.2019.147810.1001/jamaoncol.2019.1478 ↗
18. 10.1200/JCO.2018.36.15_suppl.101210.1200/JCO.2018.36.15_suppl.1012 ↗
19. 10.1200/JCO.2016.34.15_suppl.TPS207910.1200/JCO.2016.34.15_suppl.TPS2079 ↗
20. Manukian G. · Front. Oncol. · 2019 · 22 · 9
21. 10.3389/fonc.2020.60877210.3389/fonc.2020.608772 ↗
22. 10.1038/s41551-018-0203-410.1038/s41551-018-0203-4 ↗
23. 10.1021/jacs.9b1259310.1021/jacs.9b12593 ↗
24. 10.1038/nmeth.385310.1038/nmeth.3853 ↗
25. 10.1038/nprot.2006.33910.1038/nprot.2006.339 ↗
26. 10.1038/nature0766810.1038/nature07668 ↗
27. 10.1038/s41467-018-04703-w10.1038/s41467-018-04703-w ↗
28. 10.1038/nrc338010.1038/nrc3380 ↗
29. 10.1007/s00018005006710.1007/s000180050067 ↗
30. 10.1038/nm152310.1038/nm1523 ↗
31. 10.1021/accountsmr.1c0016110.1021/accountsmr.1c00161 ↗
32. 10.1002/jcp.104110020710.1002/jcp.1041100207 ↗
33. Baker S. B. · Crit. Care Resusc. · 2002 · 4 · 301
34. 10.1007/s00467-012-2175-z10.1007/s00467-012-2175-z ↗
35. 10.1038/s41467-018-06922-710.1038/s41467-018-06922-7 ↗
36. 10.1038/s43018-020-0028-410.1038/s43018-020-0028-4 ↗
37. 10.1016/j.chembiol.2020.07.00710.1016/j.chembiol.2020.07.007 ↗
38. 10.1126/sciadv.abb522310.1126/sciadv.abb5223 ↗
39. 10.1021/acsnano.1c0436310.1021/acsnano.1c04363 ↗
40. 10.1038/ni.193710.1038/ni.1937 ↗
41. 10.1073/pnas.060195610310.1073/pnas.0601956103 ↗
42. 10.1126/sciadv.aay160110.1126/sciadv.aay1601 ↗
43. 10.1016/j.tips.2017.11.00310.1016/j.tips.2017.11.003 ↗
44. 10.1039/C8CS00641E10.1039/C8CS00641E ↗
45. 10.1016/S1470-2045(19)30326-210.1016/S1470-2045(19)30326-2 ↗
46. 10.1016/j.ijrobp.2021.06.04110.1016/j.ijrobp.2021.06.041 ↗
47. 10.1002/adma.20180224410.1002/adma.201802244 ↗
48. 10.1142/S179354581642003710.1142/S1793545816420037 ↗
49. 10.1186/s12951-020-00678-310.1186/s12951-020-00678-3 ↗
50. 10.1038/s41565-020-0759-510.1038/s41565-020-0759-5 ↗
51. 10.1038/s41563-020-0755-z10.1038/s41563-020-0755-z ↗
52. 10.1021/acscentsci.1c0077910.1021/acscentsci.1c00779 ↗
53. 10.1016/j.addr.2008.03.01610.1016/j.addr.2008.03.016 ↗
54. 10.1038/nmat220210.1038/nmat2202 ↗
55. 10.1002/adma.20120044610.1002/adma.201200446 ↗
56. 10.1038/s41467-020-16339-w10.1038/s41467-020-16339-w ↗
57. 10.1038/s41467-019-12857-410.1038/s41467-019-12857-4 ↗